3-Carbonylamino-8-aminoisoquinoline compounds of formula (I):
variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the 3-carbonylamino-8-aminoisoquinoline compounds.
[EN] PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES USEFUL FOR INHIBITING JANUS KINASE<br/>[FR] DÉRIVÉS DE PYRROLO[2,3-D]PYRIMIDINE UTILES POUR INHIBER LA JANUS KINASE
申请人:PFIZER
公开号:WO2016024185A1
公开(公告)日:2016-02-18
Described herein are pyrrolo2,3-d}pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, pharmaceutical compositions containing them, and therapeutic uses thereof.
[EN] MODULATORS OF EUKARYOTIC INITIATION FACTOR 2<br/>[FR] MODULATEURS DU FACTEUR 2 D'INITIATION EUCARYOTE
申请人:DENALI THERAPEUTICS INC
公开号:WO2019183589A1
公开(公告)日:2019-09-26
The present disclosure relates generally to eukaryotic initiation factor 2B modulators of formula A, or a pharmaceutically acceptable salt, stereoisomer, or mixture of stereoisomers thereof and methods of making and using thereof.
[EN] RADIOLABELLING METHOD USING CYCLOALKYL GROUPS<br/>[FR] PROCÉDÉ DE RADIOMARQUAGE AU MOYEN DE GROUPES CYCLOALKYLE
申请人:BAYER SCHERING PHARMA AG
公开号:WO2011006621A1
公开(公告)日:2011-01-20
This invention relates to novel cyclo alkyl compounds suitable for labeling by 18F, methods of preparing such a compound, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging by positron emission tomography (PET).
PIPERINDIN-ONES DERIVATIVES, PREPARATION METHODS AND MEDICINAL USES THEREOF
申请人:[en]JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.
公开号:WO2024125451A1
公开(公告)日:2024-06-20
Piperidin-ones compound of formula (I), the preparation method thereof, pharmaceutcal compositions comprising the compounds, and the pharmaceutical uses for the treatment of disorders are disclosed.